Brief: Radiopharm Theranostics Says FY Net Loss Attributable A$34.6 Mln
31/08/2023 03:20
Aug 31 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* FY NET LOSS ATTRIBUTABLE A$34.6 MILLION
Source text for Eikon: ID:nASX4Wwv34
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%